Oculis (OCS) H.C. Wainwright 26th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 26th Annual Global Investment Conference summary
9 Jul, 2026Conference overview
Over 600 companies presented across life sciences, fintech, technology, clean tech, and more, with sector tracks and panels available live and for streaming.
H.C. Wainwright covers 636 companies with 24 senior analysts, offering corporate finance and strategic advisory services.
Clinical pipeline and recent achievements
Achieved Nasdaq listing in 2023 and Nasdaq Iceland listing in 2024, reflecting strong investor interest.
OCS-01, a topical eye drop for DME, showed positive phase III stage one results, matching efficacy of anti-VEGF injections.
OCS-02, a TNF blocker for dry eye, demonstrated strong efficacy, rapid onset, and a precision medicine approach using the TNFR1 biomarker.
OCS-05, a neuroprotective agent, is in the ACUITY trial for acute optic neuritis, with Q4 readout expected.
Market opportunities and unmet needs
DME market has a large untreated population; OCS-01 could expand treatment to early-stage and anti-VEGF non-responders.
Dry eye market is expected to double in 5–10 years, with 87% of patients unsatisfied with current treatments.
OCS-02's biomarker-driven approach could enable the first precision medicine in dry eye, improving outcomes and patient satisfaction.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Phase III programs in dry eye and optic neuritis advance, with MS and NAION expansion planned.OCS
2026 Global Healthcare Conference - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation